Kura Oncology to Report Third Quarter 2023 Financial Results
SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing…
Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing…
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company…
Global Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) represents Regeneron’s first auditory program and is currently enrolling patients…
AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive…
TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is…
WORCESTER, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical…
Highly successful inaugural CHF senior bonds priced earlier todayTwo tranches of CHF 400 million and CHF 350 million with maturities…
– Data being presented at ESGCT reflect improvements upon CasMINI, previously the smallest Cas protein known to work in human…
IRVINE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to…
Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP…